Preference for Immunotherapy with Tablets by People with Allergic Rhinitis

Mike Tankersley,1,2 Tonya Winders,3,4 Mark Aagren,5 Henrik Brandi,5 Mikkel Hasse Pedersen,6 Anne Sofie Ledgaard Loftager,6 Mette Bøgelund6 1Departments of Medicine, Pediatrics and Otolaryngology, University of Tennessee Health Science Center, Memphis, TN, USA; 2The Tankersley Clinic, Memphis, TN, US...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tankersley M, Winders T, Aagren M, Brandi H, Hasse Pedersen M, Ledgaard Loftager AS, Bøgelund M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	allergic rhinitis allergy immunotherapy discrete choice experiment patient preferences subcutaneous immunotherapy sublingual immunotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/838ffb7fa53f4ab492ed173e15553444
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:838ffb7fa53f4ab492ed173e15553444
record_format	dspace
spelling	oai:doaj.org-article:838ffb7fa53f4ab492ed173e155534442021-11-18T19:40:25ZPreference for Immunotherapy with Tablets by People with Allergic Rhinitis1177-889Xhttps://doaj.org/article/838ffb7fa53f4ab492ed173e155534442021-11-01T00:00:00Zhttps://www.dovepress.com/preference-for-immunotherapy-with-tablets-by-people-with-allergic-rhin-peer-reviewed-fulltext-article-PPAhttps://doaj.org/toc/1177-889XMike Tankersley,1,2 Tonya Winders,3,4 Mark Aagren,5 Henrik Brandi,5 Mikkel Hasse Pedersen,6 Anne Sofie Ledgaard Loftager,6 Mette Bøgelund6 1Departments of Medicine, Pediatrics and Otolaryngology, University of Tennessee Health Science Center, Memphis, TN, USA; 2The Tankersley Clinic, Memphis, TN, USA; 3Allergy & Asthma Network, Vienna, VA, USA; 4Global Allergy & Airways Patient Platform, Vienna, Austria; 5Department of Global Market Access & Public Affairs, ALK, Hørsholm, Denmark; 6Incentive Denmark, Holte, DenmarkCorrespondence: Mette Bøgelund Tel +45 2916 1222Email mb@incentive.dkBackground: People with allergic rhinitis (AR) who are not controlled on conventional therapy can be treated using allergy immunotherapy (AIT) administered as tablets, injections or drops. In the US, the use of sublingual immunotherapy as tablets (SLIT-tablets) is limited in comparison to subcutaneous immunotherapy (SCIT).Objective: This study investigated patients’ preference for SLIT-tablets vs monthly or weekly SCIT from a US patient perspective.Methods: We carried out a discrete choice experiment (DCE) consisting of two blocks with eight choice sets. Adults and caregivers of children with moderate-to-severe AR were included if they had not previously or were not currently receiving AIT. Three attributes were included in the design: the mode and frequency of administration, the risk of systemic reactions and the co-payment.Results: A total of 724 adults with AR and 665 caregivers of children with AR were included in the study. Both adults and caregivers had a significant preference for SLIT-tablets compared with both weekly and monthly injections and for less risk of anaphylactic shock. Caregivers were more risk-averse than adults when choosing their treatment, and the younger the child, the more risk-averse the caregiver. The preference for SLIT-tablets was found for both monoallergic and polyallergic adults and caregivers of monoallergic and polyallergic children. Respondents not wanting AIT for free were more risk-averse than those indicating that they wanted AIT for free.Conclusion: Our findings suggest that SLIT-tablets is the preferred route of administration for AIT among adults and caregivers of children with AR.Keywords: allergic rhinitis, allergy immunotherapy, discrete choice experiment, patient preferences, subcutaneous immunotherapy, sublingual immunotherapyTankersley MWinders TAagren MBrandi HHasse Pedersen MLedgaard Loftager ASBøgelund MDove Medical Pressarticleallergic rhinitis allergy immunotherapy discrete choice experiment patient preferences subcutaneous immunotherapy sublingual immunotherapyMedicine (General)R5-920ENPatient Preference and Adherence, Vol Volume 15, Pp 2539-2549 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	allergic rhinitis allergy immunotherapy discrete choice experiment patient preferences subcutaneous immunotherapy sublingual immunotherapy Medicine (General) R5-920
spellingShingle	allergic rhinitis allergy immunotherapy discrete choice experiment patient preferences subcutaneous immunotherapy sublingual immunotherapy Medicine (General) R5-920 Tankersley M Winders T Aagren M Brandi H Hasse Pedersen M Ledgaard Loftager AS Bøgelund M Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
description	Mike Tankersley,1,2 Tonya Winders,3,4 Mark Aagren,5 Henrik Brandi,5 Mikkel Hasse Pedersen,6 Anne Sofie Ledgaard Loftager,6 Mette Bøgelund6 1Departments of Medicine, Pediatrics and Otolaryngology, University of Tennessee Health Science Center, Memphis, TN, USA; 2The Tankersley Clinic, Memphis, TN, USA; 3Allergy & Asthma Network, Vienna, VA, USA; 4Global Allergy & Airways Patient Platform, Vienna, Austria; 5Department of Global Market Access & Public Affairs, ALK, Hørsholm, Denmark; 6Incentive Denmark, Holte, DenmarkCorrespondence: Mette Bøgelund Tel +45 2916 1222Email mb@incentive.dkBackground: People with allergic rhinitis (AR) who are not controlled on conventional therapy can be treated using allergy immunotherapy (AIT) administered as tablets, injections or drops. In the US, the use of sublingual immunotherapy as tablets (SLIT-tablets) is limited in comparison to subcutaneous immunotherapy (SCIT).Objective: This study investigated patients’ preference for SLIT-tablets vs monthly or weekly SCIT from a US patient perspective.Methods: We carried out a discrete choice experiment (DCE) consisting of two blocks with eight choice sets. Adults and caregivers of children with moderate-to-severe AR were included if they had not previously or were not currently receiving AIT. Three attributes were included in the design: the mode and frequency of administration, the risk of systemic reactions and the co-payment.Results: A total of 724 adults with AR and 665 caregivers of children with AR were included in the study. Both adults and caregivers had a significant preference for SLIT-tablets compared with both weekly and monthly injections and for less risk of anaphylactic shock. Caregivers were more risk-averse than adults when choosing their treatment, and the younger the child, the more risk-averse the caregiver. The preference for SLIT-tablets was found for both monoallergic and polyallergic adults and caregivers of monoallergic and polyallergic children. Respondents not wanting AIT for free were more risk-averse than those indicating that they wanted AIT for free.Conclusion: Our findings suggest that SLIT-tablets is the preferred route of administration for AIT among adults and caregivers of children with AR.Keywords: allergic rhinitis, allergy immunotherapy, discrete choice experiment, patient preferences, subcutaneous immunotherapy, sublingual immunotherapy
format	article
author	Tankersley M Winders T Aagren M Brandi H Hasse Pedersen M Ledgaard Loftager AS Bøgelund M
author_facet	Tankersley M Winders T Aagren M Brandi H Hasse Pedersen M Ledgaard Loftager AS Bøgelund M
author_sort	Tankersley M
title	Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
title_short	Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
title_full	Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
title_fullStr	Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
title_full_unstemmed	Preference for Immunotherapy with Tablets by People with Allergic Rhinitis
title_sort	preference for immunotherapy with tablets by people with allergic rhinitis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/838ffb7fa53f4ab492ed173e15553444
work_keys_str_mv	AT tankersleym preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis AT winderst preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis AT aagrenm preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis AT brandih preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis AT hassepedersenm preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis AT ledgaardloftageras preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis AT bøgelundm preferenceforimmunotherapywithtabletsbypeoplewithallergicrhinitis
_version_	1718420737518206976

Preference for Immunotherapy with Tablets by People with Allergic Rhinitis

Ejemplares similares